Jupiter Topco LLC Makes New Investment in Biohaven Ltd. $BHVN

Jupiter Topco LLC bought a new stake in shares of Biohaven Ltd. (NYSE:BHVN) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 8,584,675 shares of the company’s stock, valued at approximately $127,852,000. Jupiter Topco LLC owned about 5.68% of Biohaven at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. PNC Financial Services Group Inc. boosted its stake in shares of Biohaven by 113.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after buying an additional 1,268 shares during the last quarter. IFP Advisors Inc increased its position in Biohaven by 55.4% during the fourth quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock valued at $46,000 after acquiring an additional 1,450 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Biohaven by 178.4% in the fourth quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock valued at $46,000 after acquiring an additional 2,583 shares during the period. Arax Advisory Partners lifted its holdings in Biohaven by 943.3% in the fourth quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock valued at $55,000 after acquiring an additional 4,443 shares during the period. Finally, Essential Partners LLC boosted its position in Biohaven by 31.7% in the first quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock worth $76,000 after purchasing an additional 2,169 shares during the last quarter. 88.78% of the stock is owned by institutional investors.

Biohaven Trading Up 19.1%

Shares of NYSE:BHVN opened at $17.12 on Thursday. The stock has a 50 day moving average of $14.74 and a 200 day moving average of $11.83. The company has a market cap of $2.59 billion, a PE ratio of -3.69 and a beta of 1.26. Biohaven Ltd. has a 12-month low of $7.48 and a 12-month high of $18.57. The company has a current ratio of 4.73, a quick ratio of 4.73 and a debt-to-equity ratio of 21.23.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). As a group, equities research analysts expect that Biohaven Ltd. will post -3.29 EPS for the current year.

Key Biohaven News

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Major epilepsy licensing agreement: Biohaven licensed its Kv7 ion-channel platform, including lead epilepsy candidate opakalim, to SK Biopharmaceuticals in a deal potentially worth up to $795 million. The agreement includes upfront and milestone payments, plus tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim. Reuters article
• Positive Sentiment: Validation and potential funding: Opakalim is in Phase 2/3 development for focal epilepsy, and the partnership gives Biohaven a potential source of non-dilutive capital while adding a global development and commercialization partner. The deal also increased investor focus on the company’s broader pipeline. Biohaven and SK Biopharmaceuticals licensing announcement
• Positive Sentiment: Favorable trade-secret ruling: A federal court confirmed that RA Capital and Avilar Therapeutics willfully and maliciously misappropriated a Yale-developed trade secret, formalizing a $4 million award to Biohaven and Yale University. The ruling removes uncertainty around the case and provides a financial recovery for Biohaven. Biohaven trade-secret lawsuit ruling
• Neutral Sentiment: Upcoming clinical catalyst: Investors are awaiting topline results from the RISE3 trial of opakalim, expected in the second half of 2026. The licensing deal improves the commercial outlook, but milestone payments and royalties remain dependent on development, regulatory and sales outcomes. BHVN stock and upcoming trial readout

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Needham & Company LLC set a $11.00 price target on Biohaven in a research note on Monday, June 29th. Morgan Stanley raised their price objective on shares of Biohaven from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Biohaven in a research report on Tuesday, June 2nd. Bank of America reaffirmed an “underperform” rating and set a $11.00 target price (down from $12.00) on shares of Biohaven in a report on Monday, June 29th. Finally, TD Cowen reiterated a “buy” rating on shares of Biohaven in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.94.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.